Prospective, randomized, open-label, clinical trial comparing the effects of topiroxostat and febuxostat on serum uric acid, endothelial function and markers for kidney injury
Not Applicable
Recruiting
- Conditions
- Hyperuremia
- Registration Number
- JPRN-UMIN000026765
- Lead Sponsor
- Tokorozawa Heart Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1) Subjects who has a history of allergy to topiroxostat or febuxostat. 2) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 3) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 4) Subjects who has already taken mercaptopurine hydrate, azathioprine, vidarabine, didanosine. 5) Subjects whose doctor in charge do not agree to join the trial 6) Subjects who has past medical histories of active hemorrhage, ulcer, stroke, optical hemorrhage, hemorrhagic tendency.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method